Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.90 7.80 8.00 8.00 7.90 8.00 1,444,255 08:44:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 22

Evgen Pharma Share Discussion Threads

Showing 8151 to 8174 of 8175 messages
Chat Pages: 327  326  325  324  323  322  321  320  319  318  317  316  Older
DateSubjectAuthorDiscuss
20/4/2021
15:48
Judging by the size of the majority of sells for a number of weeks, i reckon mostly impatient pi's and pi's that aren't confident of Prof Chalmers efficacy data from the Covid/ARDS trial, and so fingers crossed they're all going to regret selling big time when the RNS arrives. Gl ;-)
moneymunch
20/4/2021
15:44
Indeed, but who is supplying the cheap shares?
on target
20/4/2021
15:33
A nice 650k buy, the accumulation of cheap shares continues. Gla ;-)
moneymunch
20/4/2021
13:13
First of many, including analogues of SFX-01 no doubt. Gla ;-) Juvenescence Debuts New Product to Aid in Supporting a Healthy Metabolism Metabolic Switch helps consumers support their healthy aging goals Apr 15, 2021, 11:06 ET DOUGLAS, Isle of Man, April 15, 2021 /PRNewswire/ -- Juvenescence Ltd. (Juvenescence), a life sciences company focused on modifying aging and increasing human health span and longevity, today announced the launch of its first product. Metabolic Switch is an evidence-based, breakthrough C6 Ketone Di-ester drink that, once consumed, puts the consumer in ketosis to promote a healthy metabolism. "We believe in a world where getting older doesn't mean slowing down," said Colin Watts, chief executive officer, JuvLife. "Metabolic Switch switches on your metabolism which over time can sustain energy, protect and promote lean muscle and support healthy blood sugar and immune function— all conditions associated with aging. It is a clinically proven product developed by Juvenescence to help consumers support their healthy aging goals." hTtps://www.prnewswire.com/news-releases/juvenescence-debuts-new-product-to-aid-in-supporting-a-healthy-metabolism-301269974.html
moneymunch
19/4/2021
15:00
Every chance of good news lovewins....;-) "Hopkins scientists expand their 20-year mission to understand the disease-deterring benefits of a potent plant compound found in broccoli." 25th March 2021 - John Hopkins University of Medicine, Baltimore USA “The similar results observed between the coronaviruses evaluated suggest that SFN could have broad activity against coronaviruses, a feature that may prove invaluable as new strains of pathogenic coronaviruses enter the human population.” Conclusion We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections. hTtps://www.biorxiv.org/content/10.1101/2021.03.25.437060v1.full ............. Dr Huw Jones CEO of Evgen commented: "We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021."
moneymunch
19/4/2021
14:46
Welcome back pdt. Maybe slightly more, as a worst case scenario (IMO) but certainly one would hope for a significant uplift, well beyond the potential downside risk, if the results are positive - and yes, potentially any day now, from what the company has told us. Other irons in the EVG fire beyond this too of course, so I will not be selling up in the event of bad news anyway. Please, let it be good news though!! :) GLA.
lovewinshatelosses
19/4/2021
14:41
Welcome back PDT and perfect timing, if SFX-01's preliminary efficacy assessment data any where near correlates to the John Hopkins University stunning research on Sulforaphane's therapeutic effect on Covid-19, several variants as well as ARDS etc, then every chance this will multi-bag and of course there's also multiple newsflow expected on the rest of the pipeline to add further value, which I'm hoping Huw is holding back until Prof Chalmers reports on the Covid trial, to cover all eventualities...Gl...Excitement building in anticipation. ;-)
moneymunch
19/4/2021
14:16
I was a holder here 18 months ago but sold out after the Stroke trial failure. Big loss for me :( Bought a few today since the COVID/ARDS results are potentially attractive. I assume that the top line review on the first 100 patients could arrive at any time this Quarter. Hopefully the worst case scenario of the trial being ceased will be cushioned by the cash they hold. Up to 30% share price drop from here? The upside could be multiples. As a big fan of NRF2 activation I felt I had to be in. Good luck all holders.
pdt
18/4/2021
18:59
News this week......would be nice...;-)
moneymunch
17/4/2021
20:34
Shearer was the best though...HtL:-))) 995;
moneymunch
17/4/2021
18:33
Chambers wears #9 on his back!
bocker01
17/4/2021
16:31
John Hopkins is indeed one of the worlds top medical colleges, the work in the potential therapeutic benefits of sulforaphane being originally pioneered by one of its renowned pharmacologists, Paul Talalay.
bumpa33
17/4/2021
15:40
Conflicts of interests!!!???? ;-) James D Chalmers @ProfJDChalmers · 5h Looking forward to speaking with experts on public health, education, social sciences, politics and others tonight Escaping to a post-COVID world (sounds good right?) 10:19 am · 17 Apr 2021·Twitter Web App James D Chalmers @ProfJDChalmers Researchers: we used (insert incredibly complex dataset) to test (complex hypothesis) using machine learning and (complex statistics). Also Researchers: Sorry we didn't declare our conflicts of interests, those forms are really complicated hTtps://twitter.com/ProfJDChalmers/status/1383349366912524292
moneymunch
17/4/2021
14:40
I was listening to BBC world service on radio. They were talking about Covid deaths hitting over 3 million. And how bad it is in India with this new strain of covid which hits mainly the lungs. And the John Hopkins was mentioned. It never mentioned Sulforaphane or that I think it goes to show how well John Hopkins is thought of worldwide. And we know they are in favour of our SFX1 compound. Hopefully with a good bit of luck it is a big winner
muddy_40
17/4/2021
11:08
Yep, we had a pre covid world which has gone - the talk now is of a post covid world but that implies “after covid”. I don’t think, unfortunately, that we are going to be rid of this anytime soon. Look at the research out there and it’s pretty much telling us that for now, it’s here to stay.
bumpa33
17/4/2021
11:00
Lol Bumpa, who knows but this could be bigger than Bitcoin if efficacy is proven and correlates with John Hopkins stunning research, ie the pandemic is surging out of control across the globe with the fear that the current vaccines could be ineffective to the new and ever increasing variants, and so can you imagine, SFX-01 is administered to treat those with Covid-19 and ARDS etc, but SFX-01 is also administered to stop you getting Covid-19 etc...this could be well and truly massive if that turned out to be the case....the world population dropping an SFX-01 on a regular basis to ward off the lurgy...Gl ;-))))
moneymunch
17/4/2021
10:32
Yes, “pre-treated” is quite exciting. Meanwhile the wider mkt continues to ignore - I guess “understanding” cryptos or whatever is easier :)
bumpa33
17/4/2021
10:18
httPs://figshare.com/articles/preprint/Virology/14229452?backTo=/collections/ERS_Monograph_COVID-19/5236079 a bit to take in but really worth reading, history of human coronavirus, explanation of various animal models, the role of viral shedding, currently repurposed drugs etc etc. Anti-virals will play a massive part in the battle against coronavirus - vaccines can’t do it all. It would seem from this paper that so far, the only repurposed drug to have (some, indeed any) efficacy remains Remdesivir. httPs://www.biorxiv.org/content/10.1101/2021.03.25.437060v1.full Reposting this again because I haven’t seen anyone comment on what was summed up in the last paragraph (Conclusion)... “We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections.”
bumpa33
17/4/2021
10:06
Ps 102 patients recruited to SFX-01 Covid/ARDS trial as of 16th February 2021....14 days dosing and then 28 days observation takes the first 100 trial patients to the end of March and the likely start of Prof Chalmers preliminary efficacy assessment although some of the exploratory objectives could have been ongoing since the start of the trial, blood and cell analysis etc.....Gla ;-) The trial will test the following hypothesis: Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection). ......................... Primary objective: To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia. Outcome measure:7 point ordinal scale measured on Day 15. Secondary Objectives: Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19 Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm Outcome measures: Cumulative incidence of serious Adverse events (SAEs) Discontinuation or temporary suspension of treatment .............................. Exploratory objectives (All sites) Biofire analysis of nasal swab or sputum sample Subanalysis of outcomes according to the causative pathogen Exploratory objectives (TAYSIDE ONLY) Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells Neutrophil functional studies in isolated cells Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood hTtps://star-covid19.com/
moneymunch
16/4/2021
18:48
The accumulation of cheap shares continues. Gla ;-)
moneymunch
16/4/2021
07:33
The market's awaiting Prof Chalmers preliminary efficacy assessment on SFX-01's Covid/ARDS patient trial, this will explode into life on positive data and there will be a mad dash for shares from new investors, and then Huw has multiple newsflow from the rest of the pipeline to report thereafter that could also add significant value.........Gla Holders.....Excitement building in anticipation of Prof Chalmers update that could be very close imho. ;-)
moneymunch
15/4/2021
17:22
It needs something ...SP is disastrous
amaretto1
15/4/2021
14:51
Well, we've got a raft of potential good news to look forward to this Q2 that could move the share price significantly UPwards, and every chance that Prof Chalmers preliminary efficacy assessment on SFX-01's Covid/ARDS patient trial will drop this month, where positive efficacy data could see the share price explode into life....Tick Tock.... Gla ;-)
moneymunch
14/4/2021
13:23
then your broker is looking in the wrong place (or not at all) mesquida - I have explained this before. I agree though, i don’t think this will move until we get news.
bumpa33
Chat Pages: 327  326  325  324  323  322  321  320  319  318  317  316  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210420 16:20:56